Source-linked briefing Health

Omalizumab Linked to No Epinephrine Use in Alpha-Gal Cohort

Omalizumab Linked to No Epinephrine Use in Alpha-Gal Cohort

At ACAAI 2026, a 64-patient cohort with alpha-gal syndrome reported no need for epinephrine for food reactions during omalizumab therapy. The findings suggest potential benefit but call for further study.

Original headline

Omalizumab Linked to 0 Epinephrine Use in Alpha-Gal Syndrome

Be the source

Share your story

A link, a project or a professional achievement can be the start of a Spotlight story.

Sign in with QAuth